Results 31 to 40 of about 45,859 (253)

Drug reprofiling history and potential therapies against Parkinson’s disease

Frontiers in Pharmacology, 2022
Given the high whittling down rates, high costs, and moderate pace of new medication, revelation, and improvement, repurposing “old” drugs to treat typical and uncommon illnesses is progressively becoming an appealing proposition. Drug repurposing is the
Komal Latif, Aman Ullah, Anastasiia D. Shkodina, Anastasiia D. Shkodina, Dmytro I. Boiko, Zakia Rafique, Badrah S. Alghamdi, Badrah S. Alghamdi, Mohamed A. Alfaleh, Mohamed A. Alfaleh, Ghulam Md. Ashraf   +10 more
doaj   +1 more source

A machine learning and network framework to discover new indications for small molecules.

PLoS Computational Biology, 2020
Drug repurposing, identifying novel indications for drugs, bypasses common drug development pitfalls to ultimately deliver therapies to patients faster. However, most repurposing discoveries have been led by anecdotal observations (e.g.
Coryandar Gilvary, Jamal Elkhader, Neel Madhukar, Claire Henchcliffe, Marcus D Goncalves, Olivier Elemento   +5 more
doaj   +1 more source

Drug Repurposing for Rare Orphan Diseases Using Machine Learning Techniques

Proceedings of the International Florida Artificial Intelligence Research Society Conference, 2022
New drug discovery is a time-consuming and costly process. Several drugs have been in clinical trials for a very long period. Finding a new target for existing medications can be an effective strategy to reduce the lengthy and costly drug development ...
Rajesh Manicavasaga, Prabin B Lamichhane, Prajjwal Kandel, Douglas A. Talbert   +3 more
doaj   +1 more source

Old Drugs, New Indications (Review)

Разработка и регистрация лекарственных средств, 2023
Introduction. The drug can be used in the treatment of one disease and for the prevention and treatment of another pathological process. This is possible due to the repurposing of medicines.
I. I. Miroshnichenko, E. A. Valdman, I. I. Kuz'min   +2 more
doaj   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors

Pharmacology Research & Perspectives
Cancer medicines often have narrow therapeutic windows; toxicity can be severe and sometimes fatal, but inadequate dose intensity reduces efficacy and survival.
Jennifer H. Martin, Peter Galettis, Alex Flynn, Jennifer Schneider   +3 more
doaj   +1 more source

A novel drug repurposing approach for non-small cell lung cancer using deep learning.

PLoS ONE, 2020
Drug repurposing is an attractive and pragmatic way offering reduced risks and development time in the complicated process of drug discovery. In the past, drug repurposing has been largely accidental and serendipitous. The most successful examples so far
Bingrui Li, Chan Dai, Lijun Wang, Hailong Deng, Yingying Li, Zheng Guan, Haihong Ni   +6 more
doaj   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Knowledge-driven drug repurposing using a comprehensive drug knowledge graph

Health Informatics Journal, 2020
Due to the huge costs associated with new drug discovery and development, drug repurposing has become an important complement to the traditional de novo approach.
Yongjun Zhu, Chao Che, Bo Jin, Ningrui Zhang, Chang Su, Fei Wang   +5 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source